These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9860475)

  • 1. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.
    van Ijken MG; de Bruijn EA; de Boeck G; ten Hagen TL; van der Sijp JR; Eggermont AM
    Ann Surg; 1998 Dec; 228(6):763-70. PubMed ID: 9860475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs.
    van IJken MG; de Bruijn EA; ten Hagen TL; de Boeck G; van Eijck CH; Eggermont AM
    Eur J Surg Oncol; 2004 Aug; 30(6):699-707. PubMed ID: 15256247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
    Borel Rinkes IH; de Vries MR; Jonker AM; Swaak TJ; Hack CE; Nooyen PT; Wiggers T; Eggermont AM
    Br J Cancer; 1997; 75(10):1447-53. PubMed ID: 9166936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A newly-established method of isolated hypoxic hepatic perfusion].
    Wang Xd; Yang Rj; Sun Hl; Zhang Hz
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Apr; 40(2):200-4. PubMed ID: 18458700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
    van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.
    Eggermont AM; van IJken MG; van Etten B; van der Sijp JR; ten Hagen TL; Wiggers T; Oudkerk M; de Boeck G; de Bruijn EA
    Hepatogastroenterology; 2000; 47(33):776-81. PubMed ID: 10919031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
    van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
    J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model.
    Nakamoto T; Inagawa H; Takagi K; Tashiro K; Yoshimura H; Nishizawa T; Honda T; Kanou J; Muto Y; Amm E; Soma G
    Anticancer Res; 2000; 20(1C):619-22. PubMed ID: 10769705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
    De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
    Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
    Libutti SK; Barlett DL; Fraker DL; Alexander HR
    J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.
    Pilati P; Mocellin S; Rossi CR; Ori C; Innocente F; Scalerta R; Ceccherini M; Da Pian PP; Nitti D; Lise M
    World J Surg; 2004 Aug; 28(8):775-81. PubMed ID: 15457357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
    Nakamoto T; Inagawa H; Takagi K; Soma G
    Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
    Guadagni S; Santinami M; Patuzzo R; Pilati PL; Miotto D; Deraco M; Rossi CR; Fiorentini G; Di Filippo F; Valenti M; Amicucci G
    Melanoma Res; 2003 Feb; 13(1):51-8. PubMed ID: 12569285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
    de Vries MR; Borel Rinkes IH; van de Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Vahrmeijer AL; Eggermont AM
    Recent Results Cancer Res; 1998; 147():107-19. PubMed ID: 9670273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
    Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
    J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
    Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
    Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases.
    Oldhafer KJ; Frerker MK; Lang H; Fauler J; Flemming P; Schmoll E; Nadalin S; Moreno L; Pichlmayr R
    J Invest Surg; 1998; 11(6):393-400. PubMed ID: 9895113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.